Vasculitis: Clinical Trials

35 trials for Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 completed. 35 Phase 1, 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 135Completed 35
Phase 214Completed 14

Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Secukinumab - Giant Cell Arteritis, Polymyalgia Rheumatica
Phase 1CompletedNovartis Pharmaceuticals652024-03-272026-04-01
JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
Ruxolitinib - Kohlmeier Degos Disease With Neurologic Involvement, Kohlmeier-Degos Disease
Phase 1 / Phase 2CompletedNational Heart, Lung, and Blood Institute (NHLBI)12023-09-282026-02-03
The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
STSA-1002 subcutaneous injection - Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Phase 1CompletedStaidson (Beijing) Biopharmaceuticals Co., Ltd202023-01-312023-05-26
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis
Phase 1 / Phase 2CompletedStaidson (Beijing) Biopharmaceuticals Co., Ltd932022-02-222025-08-07
Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
Tocilizumab Prefilled Syringe - Rheumatoid Arthritis, Giant Cell Arteritis
Phase 1CompletedSyneos Health3002021-05-312024-01-05
A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants
Avacopan, Moxifloxacin, Placebo for avacopan - Electrocardiography
Phase 1CompletedAmgen582019-11-082023-08-14
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
Tocilizumab - Giant Cell Arteritis
Phase 1CompletedHoffmann-La Roche242019-08-052021-12-22
Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Tocilizumab, Glucocorticoids - Giant Cell Arteritis
Phase 1 / Phase 2CompletedInsel Gruppe AG, University Hospital Bern182018-12-012021-06-22
A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment
Avacopan - Hepatic Impairment
Phase 1CompletedAmgen242018-04-172023-08-22
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
CCX168, Placebo - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1CompletedAmgen802017-10-232023-08-14
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
CCX168, Midazolam, Celecoxib - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1CompletedAmgen322016-01-142023-08-22
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
CCX168 - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1CompletedAmgen162015-12-032023-08-14
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Anakinra - Kawasaki Disease
Phase 1 / Phase 2CompletedUniversity of California, San Diego222014-11-012024-03-04
A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
[14C]CCX168 - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1CompletedAmgen62014-10-202023-08-22
Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis
triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis
Phase 1 / Phase 2CompletedClearside Biomedical, Inc.112013-02-012021-02-21
Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study
Intravitreal Infliximab - Behçet's Disease, Uveitis
Phase 1 / Phase 2CompletedCairo University202013-01-012015-12-03
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
Atorvastatin - Kawasaki Disease
Phase 1 / Phase 2CompletedUniversity of California, San Diego342012-07-012020-05-06
Anakinra for Behcet s Disease
Anakinra - Autoimmune Connective Tissue Disorder, Immune System Diseases
Phase 1 / Phase 2CompletedNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)62011-09-012017-05-12
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants
CCX168, Placebo - Vasculitis, Systemic Lupus Erythematosus (SLE)
Phase 1CompletedAmgen482009-12-212023-08-09
Autologous Endothelial Progenitor Cells (EPCs) From Peripheral Blood in the Treatment of Critical Limb Ischemia
Endothelial progenitor cells intramuscular implant - Critical Limb Ischemia
Phase 1 / Phase 2CompletedFondazione IRCCS Policlinico San Matteo di Pavia82009-01-012012-06-14

Showing 20 of 35. Sign in to see all of them.

Narrower conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8)  ·  Giant Cell Arteritis (6)  ·  Granulomatosis with Polyangiitis (5)  ·  Mucocutaneous Lymph Node Syndrome (4)  ·  Vascular Diseases (4)  ·  Cardiovascular Diseases (3)  ·  Inflammation (3)  ·  Lupus Erythematosus, Systemic (3)  ·  Uveitis (3)  ·  Behcet Syndrome (2)  ·  Churg-Strauss Syndrome (2)  ·  Uveitis, Posterior (2)  ·  Arthritis, Rheumatoid (1)  ·  Atherosclerosis (1)

Broader conditions

Cardiovascular Diseases (32)  ·  Skin and Connective Tissue Diseases (32)  ·  Skin Diseases (31)  ·  Vascular Diseases (31)  ·  Skin Diseases, Vascular (30)  ·  Immune System Diseases (25)  ·  Autoimmune Diseases (23)  ·  Systemic Vasculitis (15)  ·  Hemic and Lymphatic Diseases (9)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8)  ·  Brain Diseases (8)  ·  Central Nervous System Diseases (8)  ·  Cerebrovascular Disorders (8)  ·  Nervous System Diseases (8)

Interventions

avacopan (6)  ·  tocilizumab (3)  ·  Glucocorticoids (2)  ·  Interleukin 1 Receptor Antagonist Protein (2)  ·  Mycophenolic Acid (2)  ·  mepolizumab (2)  ·  Abatacept (1)  ·  Adrenal Cortex Hormones (1)  ·  Atorvastatin (1)  ·  BDB001 (1)  ·  Celecoxib (1)  ·  Cell- and Tissue-Based Therapy (1)  ·  Cyclophosphamide (1)  ·  Heparin (1)  ·  Immunoglobulins, Intravenous (1)

Sponsors

Amgen (7)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  University of California, San Diego (3)  ·  National Institutes of Health Clinical Center (CC) (2)  ·  Staidson (Beijing) Biopharmaceuticals Co., Ltd (2)  ·  Brigham and Women's Hospital (1)  ·  Cairo University (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Clearside Biomedical, Inc. (1)  ·  Fondazione IRCCS Policlinico San Matteo di Pavia (1)  ·  French National Agency for Research on AIDS and Viral Hepatitis (1)  ·  Gilead Sciences (1)  ·  Hoffmann-La Roche (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  Lantheus Medical Imaging (1)

Countries

United States (25)  ·  Switzerland (4)  ·  Canada (2)  ·  Italy (2)  ·  Australia (1)  ·  China (1)  ·  Czechia (1)  ·  France (1)  ·  India (1)  ·  Japan (1)  ·  New Zealand (1)  ·  Portugal (1)  ·  Spain (1)  ·  Taiwan (1)

Top investigators

Jane C Burns, MD (2)  ·  Adriana H Tremoulet, MD (1)  ·  Attilio Odero, Professor (1)  ·  Carol A. Langford, MD, MHS (1)  ·  Cornelia D Cudrici, M.D. (1)  ·  Fernando C. Fervenza, M.D., Ph.D. (1)  ·  Jane C Burns, M.D. (1)  ·  Mahmoud Soliman, MD PhD (1)  ·  Marc E. Rothenberg, MD (1)  ·  Martin K Kankam, Doctor (1)  ·  Michael Wechsler, MD (1)  ·  Minghui Zhao, Postdoc (1)  ·  Narinder Paul, FRCP C (1)

Results publications

PMID 20093349, PMID 22129253, PMID 24323392, PMID 25858045, PMID 26526721, PMID 27080929, PMID 27923814, PMID 27980877, PMID 28335798, PMID 33950298, PMID 34117737, PMID 35659282, PMID 37287970, PMID 38287611, PMID 38973157, PMID 38993026, PMID 42532045

NIH funding

2018 (2), 2023 (1), U54AR057319 (1)